Please assess the completion status of the following clinical trial:

Trial Title: Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent before any study related procedures are performed.~2. A qualifying post-operative T or I troponin elevation (≥2x ULN of assay within 7 days of index surgery and during the index hospitalization).~3. Men and women ≥40 years of age if troponin elevation was identified as part of routine post-operative clinical care OR~4. Men and women ≥55 years of age if troponin elevation was identified post-operatively as part of screening for the study.~5. Undergone non-cardiac surgery requiring an overnight hospital stay.~6. Women of childbearing potential who are sexually active must have a negative pregnancy test at enrollment and agree to use adequate contraception from screening until 30 days after receiving the last dose of study drug.~7. Able to be randomized within 35 days following the index surgery.~Exclusion Criteria:~1. Post-operative ST-elevation Myocardial Infarction (STEMI).~2. Post-operative high-risk non-STEMI, defined as patients with elevated troponin with either:~   1. active Ischemic EKG changes (≥2 mm of ST-segment depression in at least 2 adjacent leads)~  2. ongoing hemodynamic instability thought to be ischemia mediated or~  3. persistent anginal symptoms.~3. Planned or urgent coronary angiography/revascularization.~4. A current or ongoing indication for dual antiplatelet therapy (DAPT) as determined by the patient's physician.~5. History of intracranial hemorrhage~6. Bleeding disorder or active bleeding that prevents ticagrelor or aspirin administration.~7. Taking any of the following medications at the time of randomization: vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban , fondaparinux, cilostazol, vorapaxar or LMWHs.~8. Renal dialysis.~9. Hepatic impairment with transaminase ≥3x ULN at time of randomization.~10. Known contra-indication for use of ticagrelor.~11. Estimated life expectancy of \<1 year.~12. Enrolled in another ongoing drug or device research protocol~13. A definite non-ischemic explanation for troponin elevation, such as myocarditis or pulmonary embolism.~14. A documented hypersensitivity to aspirin.~15. Hypersensitivity to ticagrelor or any component of the product.~16. Neurological or ophthalmic surgery during the index hospitalization.~17. Patients taking strong CYP3A inhibitors and/or CYP3A inducers that cannot be stopped for the course of the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ticagrelor (Type: EXPERIMENTAL): ticagrelor 90mg bid
- aspirin (Type: ACTIVE_COMPARATOR): Patients in the aspirin arm will receive aspirin 81 mg daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).